GB0316294D0 - Conjugated biological molecules and their preparation - Google Patents

Conjugated biological molecules and their preparation

Info

Publication number
GB0316294D0
GB0316294D0 GBGB0316294.8A GB0316294A GB0316294D0 GB 0316294 D0 GB0316294 D0 GB 0316294D0 GB 0316294 A GB0316294 A GB 0316294A GB 0316294 D0 GB0316294 D0 GB 0316294D0
Authority
GB
United Kingdom
Prior art keywords
group
general formula
protein
compound
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0316294.8A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abzena UK Ltd
Original Assignee
Polytherics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27742023&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GB0316294(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polytherics Ltd filed Critical Polytherics Ltd
Priority to GBGB0316294.8A priority Critical patent/GB0316294D0/en
Publication of GB0316294D0 publication Critical patent/GB0316294D0/en
Priority to DK09167191.7T priority patent/DK2133099T3/en
Priority to EP10175140.2A priority patent/EP2253330B1/en
Priority to ES09167191.7T priority patent/ES2632515T3/es
Priority to EP09167191.7A priority patent/EP2133099B1/en
Priority to DE602004022824T priority patent/DE602004022824D1/de
Priority to DK04743335T priority patent/DK1648518T3/da
Priority to EP20100175143 priority patent/EP2277550B1/en
Priority to ES04743335T priority patent/ES2331004T3/es
Priority to ES10175140.2T priority patent/ES2549427T3/es
Priority to CN2004800198144A priority patent/CN1822860B/zh
Priority to PCT/GB2004/002994 priority patent/WO2005007197A2/en
Priority to AT04743335T priority patent/ATE440620T1/de
Priority to AU2004257448A priority patent/AU2004257448B2/en
Priority to US10/564,340 priority patent/US7595292B2/en
Priority to PL04743335T priority patent/PL1648518T3/pl
Priority to EP04743335A priority patent/EP1648518B1/en
Priority to CN2010101399434A priority patent/CN101792525B/zh
Priority to DK10175140.2T priority patent/DK2253330T3/en
Priority to JP2006518372A priority patent/JP4958549B2/ja
Priority to KR1020067000278A priority patent/KR101152500B1/ko
Priority to PL10175140T priority patent/PL2253330T3/pl
Priority to ES10175143.6T priority patent/ES2542531T3/es
Priority to DK10175143.6T priority patent/DK2277550T3/en
Priority to US12/458,931 priority patent/US7939630B2/en
Priority to AU2010257308A priority patent/AU2010257308B2/en
Priority to US13/077,980 priority patent/US8816051B2/en
Priority to JP2011170597A priority patent/JP5349552B2/ja
Priority to US14/444,859 priority patent/US9439974B2/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/91—Polymers modified by chemical after-treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F10/00—Homopolymers and copolymers of unsaturated aliphatic hydrocarbons having only one carbon-to-carbon double bond
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08F—MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS
    • C08F8/00—Chemical modification by after-treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
GBGB0316294.8A 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation Ceased GB0316294D0 (en)

Priority Applications (29)

Application Number Priority Date Filing Date Title
GBGB0316294.8A GB0316294D0 (en) 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation
ES10175143.6T ES2542531T3 (es) 2003-07-11 2004-07-12 Procedimiento de preparación de moléculas biológicas conjugadas
DK10175143.6T DK2277550T3 (en) 2003-07-11 2004-07-12 A process for the preparation of conjugated biological molecules
AU2004257448A AU2004257448B2 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
EP04743335A EP1648518B1 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
ES09167191.7T ES2632515T3 (es) 2003-07-11 2004-07-12 Moléculas biológicas conjugadas y su preparación
EP09167191.7A EP2133099B1 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
DE602004022824T DE602004022824D1 (de) 2003-07-11 2004-07-12 Konjugierte biologische moleküle und ihre herstellung
DK04743335T DK1648518T3 (da) 2003-07-11 2004-07-12 Konjugerede biologiske molekyler og deres fremstilling
EP20100175143 EP2277550B1 (en) 2003-07-11 2004-07-12 Process for the preparation of conjugated biological molecules.
ES04743335T ES2331004T3 (es) 2003-07-11 2004-07-12 Moleculas biologicas conjugadas y su preparacion.
ES10175140.2T ES2549427T3 (es) 2003-07-11 2004-07-12 Moléculas biológicas conjugadas y su preparación
CN2004800198144A CN1822860B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备
PCT/GB2004/002994 WO2005007197A2 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
AT04743335T ATE440620T1 (de) 2003-07-11 2004-07-12 Konjugierte biologische moleküle und ihre herstellung
DK09167191.7T DK2133099T3 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
US10/564,340 US7595292B2 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
PL04743335T PL1648518T3 (pl) 2003-07-11 2004-07-12 Skoniugowane cząsteczki biologiczne i ich wytwarzanie
EP10175140.2A EP2253330B1 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
CN2010101399434A CN101792525B (zh) 2003-07-11 2004-07-12 偶联生物分子及其制备
DK10175140.2T DK2253330T3 (en) 2003-07-11 2004-07-12 Conjugated biological molecules and their preparation
JP2006518372A JP4958549B2 (ja) 2003-07-11 2004-07-12 複合生物学的分子及びそれらの調製
KR1020067000278A KR101152500B1 (ko) 2003-07-11 2004-07-12 접합된 생물학적 분자 및 그의 제조방법
PL10175140T PL2253330T3 (pl) 2003-07-11 2004-07-12 Skoniugowane cząsteczki biologiczne i ich otrzymywanie
US12/458,931 US7939630B2 (en) 2003-07-11 2009-07-28 Conjugated biological molecules and their preparation
AU2010257308A AU2010257308B2 (en) 2003-07-11 2010-12-20 Conjugated biological molecules and their preparation
US13/077,980 US8816051B2 (en) 2003-07-11 2011-03-31 Conjugated biological molecules and their preparation
JP2011170597A JP5349552B2 (ja) 2003-07-11 2011-08-04 複合生物学的分子及びそれらの調製
US14/444,859 US9439974B2 (en) 2003-07-11 2014-07-28 Conjugated biological molecules and their preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0316294.8A GB0316294D0 (en) 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation

Publications (1)

Publication Number Publication Date
GB0316294D0 true GB0316294D0 (en) 2003-08-13

Family

ID=27742023

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0316294.8A Ceased GB0316294D0 (en) 2003-07-11 2003-07-11 Conjugated biological molecules and their preparation

Country Status (13)

Country Link
US (4) US7595292B2 (https=)
EP (4) EP2253330B1 (https=)
JP (2) JP4958549B2 (https=)
KR (1) KR101152500B1 (https=)
CN (2) CN1822860B (https=)
AT (1) ATE440620T1 (https=)
AU (2) AU2004257448B2 (https=)
DE (1) DE602004022824D1 (https=)
DK (4) DK2253330T3 (https=)
ES (4) ES2632515T3 (https=)
GB (1) GB0316294D0 (https=)
PL (2) PL2253330T3 (https=)
WO (1) WO2005007197A2 (https=)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5207590B2 (ja) 2002-12-26 2013-06-12 マウンテン ビュー ファーマシューティカルズ，インコーポレイテッド 増強された生物学的能力を有するインターフェロン−βのポリマー結合体
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
US7046714B2 (en) * 2003-09-10 2006-05-16 Intel Corporation Method and apparatus for Raman ring resonator based laser/wavelength converter
JP4942643B2 (ja) * 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
KR20080068004A (ko) * 2005-08-15 2008-07-22 아라나 테라퓨틱스 리미티드 뉴 월드 영장류 구조형성영역을 가진 조작 항체
US7846439B2 (en) * 2006-02-01 2010-12-07 Cephalon Australia Pty Ltd Domain antibody construct
US20080139790A1 (en) * 2006-12-08 2008-06-12 Jennings Philip A Chimeric antibodies
US8575397B2 (en) 2007-02-14 2013-11-05 Biocompatibles Uk Limited Derivatisation of biological molecules
GB0708376D0 (en) 2007-05-01 2007-06-06 Alligator Bioscience Ab Novel polypeptides and uses thereof
US8658148B2 (en) 2007-06-22 2014-02-25 Genzyme Corporation Chemically modified dendrimers
TWI360535B (en) * 2007-08-30 2012-03-21 Univ Nat Sun Yat Sen Sulfur-containing compound, method of preparation
CN101820920B (zh) * 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
DK2280734T3 (da) * 2008-04-24 2014-05-26 Cantab Biopharmaceuticals Patents Ltd Faktor-ix-konjugater med forlængede halveringstider
AU2009270405B2 (en) 2008-06-30 2014-06-05 Esbatech, An Alcon Biomedical Research Unit Llc Functionalized polypeptides
EP2769711A1 (en) 2008-07-10 2014-08-27 ESBATech, an Alcon Biomedical Research Unit LLC Methods and Compositions for Enhanced Delivery of Macromolecules
AU2009275358C1 (en) * 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
GB0817978D0 (en) * 2008-10-01 2008-11-05 Imp Innovations Ltd Peptides
CN102272151B (zh) * 2008-11-04 2014-08-20 詹森药业有限公司 Crhr2肽激动剂及其用途
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
GB0922354D0 (en) 2009-12-21 2010-02-03 Polytherics Ltd Novel polymer conjugates
GB0912485D0 (en) 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
WO2011005540A1 (en) 2009-06-22 2011-01-13 Burnham Institute For Medical Research Methods and compositions using peptides and proteins with c-terminal elements
GB0916578D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
GB0916576D0 (en) 2009-09-22 2009-10-28 Malmsten Nils M Polypeptides and uses thereof
FI124016B (fi) * 2009-10-26 2014-01-31 Vapo Oy Menetelmä biomassakuivattimessa käytetyn kuivatusilman lämmittämiseksi välipiirinesteen avulla sekä vesi-glykoliseoksen tai sitä vastaavan jäätymättömän välipiirinesteen käyttö biomassakuivattimessa käytetyn kuivatusilman lämmittämiseksi
US20110105397A1 (en) * 2009-11-04 2011-05-05 Gengo Peter J Method for treating heart failure with stresscopin-like peptides
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
GB201007357D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIII
WO2012118778A1 (en) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Truncated car peptides and methods and compositions using truncated car peptides
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
AU2012262488A1 (en) 2011-05-31 2014-01-16 Airware, Inc. Re-calibration of AB NDIR gas sensors
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
WO2013177481A1 (en) 2012-05-25 2013-11-28 Immunogen, Inc. Benzodiazepines and conjugates thereof
GB201210770D0 (en) 2012-06-18 2012-08-01 Polytherics Ltd Novel conjugation reagents
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents
EP2861261A2 (en) * 2012-06-19 2015-04-22 Polytherics Limited Process for preparation of antibody conjugates and antibody conjugates
NO2789793T3 (https=) 2012-10-24 2018-01-27
US20150290342A1 (en) 2012-10-24 2015-10-15 Polytherics Limited Drug-protein conjugates
ES2732574T3 (es) * 2012-11-30 2019-11-25 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
WO2014093379A1 (en) 2012-12-10 2014-06-19 Mersana Therapeutics, Inc. Auristatin compounds and conjugates thereof
CA2892863C (en) 2012-12-10 2022-03-15 Mersana Therapeutics, Inc. Polymeric scaffold based on phf for targeted drug delivery
WO2014093640A1 (en) 2012-12-12 2014-06-19 Mersana Therapeutics,Inc. Hydroxy-polmer-drug-protein conjugates
JP6847388B2 (ja) 2013-03-15 2021-03-31 レゲネロン ファーマシューティカルス，インコーポレーテッド 生物活性分子、そのコンジュゲート、及び治療用途
GB201308738D0 (en) * 2013-05-15 2013-06-26 Polytherics Ltd Novel polymer conjugates
BR112016004023A2 (pt) 2013-08-26 2022-11-16 Regeneron Pharma Composição, métodos para preparar uma composição e para tratar uma doença, e, composto
JP6282745B2 (ja) 2013-09-12 2018-02-21 ハロザイム インコーポレイテッド 修飾抗上皮成長因子受容体抗体およびその使用法
BR112015032713B1 (pt) 2013-09-17 2023-03-21 Obi Pharma, Inc Composto, composição farmacêutica, uso de uma quantidade terapeuticamente efetiva da composição farmacêutica, e uso do composto
KR102087850B1 (ko) 2013-10-11 2020-03-12 메르사나 테라퓨틱스, 인코포레이티드 단백질-고분자-약물 접합체
ES2754397T3 (es) 2013-10-11 2020-04-17 Asana Biosciences Llc Conjugados de proteína-polímero-fármaco
EA201691075A1 (ru) 2013-11-26 2016-09-30 Новартис Аг Способы оксимной конъюгации с кетон-модифицированными полипептидами
GB201403875D0 (en) 2014-03-05 2014-04-16 Cantargia Ab Novel antibodies and uses thereof
ES2792598T3 (es) 2014-05-23 2020-11-11 Novartis Ag Métodos para preparar conjugados a partir de proteínas que contienen disulfuro
US9951141B2 (en) 2014-06-02 2018-04-24 Regeneron Pharmaceuticals, Inc. Antibody-drug conjugates, their preparation and their therapeutic use
GB201413913D0 (en) 2014-08-06 2014-09-17 Cantargia Ab Novel antibodies and uses thereof
EP3218009B1 (en) 2014-10-14 2021-04-07 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg
AU2016214317B2 (en) * 2015-02-05 2022-01-13 Ablynx N.V. Nanobody dimers linked via C-terminally engineered cysteins
BR112017020149A8 (pt) 2015-03-27 2023-05-02 Regeneron Pharma Derivados de maitansinoide, conjugados dos mesmos e métodos de uso
US10098960B2 (en) 2015-04-03 2018-10-16 Ucl Business Plc Polymer conjugate
US10509035B2 (en) 2015-08-07 2019-12-17 Gamamabs Pharma Sa Antibodies, antibody drug conjugates and methods of use
US10935544B2 (en) 2015-09-04 2021-03-02 Obi Pharma, Inc. Glycan arrays and method of use
EP3402825A1 (en) 2016-01-12 2018-11-21 Crescendo Biologics Limited Molecules that bind prostate specific membrane antigen (psma)
GB201601136D0 (en) 2016-01-21 2016-03-09 Mörgelin Matthias And Abdillahi Suado M Novel polypeptides and medical uses thereof
BR112018014759B1 (pt) 2016-01-25 2024-02-27 Regeneron Pharmaceuticals, Inc Compostos derivados de maitasinoide e seus conjugados, composição compreendendo os mesmos, seus métodos de fabricação e uso
WO2017161206A1 (en) 2016-03-16 2017-09-21 Halozyme, Inc. Conjugates containing conditionally active antibodies or antigen-binding fragments thereof, and methods of use
US10980894B2 (en) 2016-03-29 2021-04-20 Obi Pharma, Inc. Antibodies, pharmaceutical compositions and methods
BR112018070097A2 (pt) 2016-03-29 2019-02-12 Obi Pharma, Inc. anticorpo, hibridoma, composição farmacêutica, método para tratar câncer em um indivíduo, método para inibir a proliferação de células cancerígenas, método para diagnosticar o câncer em um indivíduo, método para tratar um paciente humano, método para fazer imagens de um indivíduo, conjugado de fármaco-anticorpo (adc), método para tratar câncer, anticorpo biespecífico e método para preparar uma população de anticorpos homogêneos
CN109152845B (zh) 2016-04-14 2022-07-12 宝力泰锐克斯有限公司 含有在环内包含至少两个(-ch2-ch2-o-)单元的接头的缀合物和缀合试剂
KR20230110820A (ko) 2016-04-22 2023-07-25 오비아이 파머 인코퍼레이티드 글로보 계열 항원을 통한 면역 활성화 또는 면역 조정에의한 암 면역요법
GB201608936D0 (en) 2016-05-20 2016-07-06 Polytherics Ltd Novel conjugates and novel conjugating reagents
EP3464379B1 (en) 2016-06-06 2023-09-27 Abzena (UK) Limited Antibodies, uses thereof and conjugates thereof
CN110072545A (zh) 2016-07-27 2019-07-30 台湾浩鼎生技股份有限公司 免疫原性/治疗性聚糖组合物及其用途
US11643456B2 (en) 2016-07-29 2023-05-09 Obi Pharma, Inc. Human antibodies, pharmaceutical compositions and methods
GB201614162D0 (en) 2016-08-18 2016-10-05 Polytherics Ltd Antibodies, uses thereof and conjugates thereof
GB201615725D0 (en) 2016-09-15 2016-11-02 Polytherics Ltd Novel cytotoxic agents and conjugates thereof
TWI822055B (zh) 2016-11-21 2023-11-11 台灣浩鼎生技股份有限公司 共軛生物分子、醫藥組成物及方法
US11135307B2 (en) 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
AU2018290330A1 (en) 2017-06-22 2020-01-02 Mersana Therapeutics, Inc. Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates
GB201711068D0 (en) 2017-07-10 2017-08-23 Crescendo Biologics Ltd Therapeutic molecules binding PSMA
TW202504930A (zh) 2018-06-27 2025-02-01 台灣浩鼎生技股份有限公司 用於糖蛋白工程的糖苷合成酶變體及其使用方法
GB201814281D0 (en) 2018-09-03 2018-10-17 Femtogenix Ltd Cytotoxic agents
GB201901197D0 (en) 2019-01-29 2019-03-20 Femtogenix Ltd G-A Crosslinking cytotoxic agents
GB201909298D0 (en) 2019-06-28 2019-08-14 Colzyx Ab Novel compositions and uses thereof
GB2597532A (en) 2020-07-28 2022-02-02 Femtogenix Ltd Cytotoxic compounds
GB202016456D0 (en) 2020-10-16 2020-12-02 Colzyx Ab Novel bioactive peptide combinations and uses thereof
CA3261603A1 (en) 2022-07-15 2024-01-18 Pheon Therapeutics Ltd ANTIBODY-DRUG CONJUGATES
CN115304524A (zh) * 2022-07-21 2022-11-08 湖南大学 一种β-酰基烯丙基甲基砜类化合物及其高效合成方法
WO2024067841A1 (zh) 2022-09-30 2024-04-04 上海迪诺医药科技有限公司 苯并氮杂卓衍生物、含其的偶联物及其应用
AU2023393382A1 (en) 2022-12-14 2025-06-19 Pheon Therapeutics Ltd Cytotoxic compounds
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US680343A (en) * 1899-04-15 1901-08-13 Johan Peter Moeller Glove.
US3828412A (en) * 1971-03-19 1974-08-13 Dunham Bush Inc Method of forming high integrity epoxy joint between aluminum tubes
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
WO1988005433A1 (en) 1987-01-15 1988-07-28 Celltech Limited Thiol-reactive cross-linking reagents
ES2136595T5 (es) 1989-04-19 2004-04-01 Enzon, Inc. Carbonatos activos de oxidos de polialquileno para la modificacion de polipeptidos.
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
JP3631755B2 (ja) * 1994-03-23 2005-03-23 明治製菓株式会社 ポリオキシエチレン含有脂質二本鎖誘導体
US5877224A (en) * 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
GB9713979D0 (en) 1997-07-03 1997-09-10 Univ Nottingham Method for attaching peg to macromolecules
JP4078032B2 (ja) * 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6153655A (en) * 1998-04-17 2000-11-28 Enzon, Inc. Terminally-branched polymeric linkers and polymeric conjugates containing the same
EE05214B1 (et) * 1998-04-28 2009-10-15 Applied Research Systems ARS Holding N.V. Polool-IFN- β konjugaat, selle valmistamismeetod ja farmatseutiline kompositsioon
WO2001005819A1 (en) * 1999-07-15 2001-01-25 Kuhnil Pharm. Co., Ltd. Novel water soluble-cyclosporine conjugated compounds
US6828412B1 (en) 1999-09-03 2004-12-07 School Of Pharmacy, University Of London Degradable polymers
AU7346400A (en) 1999-09-03 2001-04-10 School Of Pharmacy, University Of London, The Degradable polymers
AU7025600A (en) 1999-09-08 2001-04-10 School Of Pharmacy, University Of London, The Uniform molecular weight polymers
GB0316294D0 (en) * 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
GB0400264D0 (en) * 2004-01-07 2004-02-11 Polytherics Ltd Complexes
US8575397B2 (en) * 2007-02-14 2013-11-05 Biocompatibles Uk Limited Derivatisation of biological molecules
CN101820920B (zh) * 2007-10-09 2014-08-06 宝力泰锐克斯有限公司 新的缀合蛋白质和肽
AU2009275358C1 (en) * 2008-07-21 2015-09-24 Polytherics Limited Novel reagents and method for conjugating biological molecules
EP2403538B1 (en) * 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method
US9650331B2 (en) 2012-06-18 2017-05-16 Polytherics Limited Conjugation reagents

Also Published As

Publication number Publication date
US7595292B2 (en) 2009-09-29
AU2004257448A1 (en) 2005-01-27
PL1648518T3 (pl) 2010-02-26
ES2632515T3 (es) 2017-09-13
EP2133099A2 (en) 2009-12-16
EP2253330A3 (en) 2011-03-09
KR101152500B1 (ko) 2012-07-05
EP1648518B1 (en) 2009-08-26
US7939630B2 (en) 2011-05-10
EP2277550A1 (en) 2011-01-26
EP2253330B1 (en) 2015-08-19
EP2133099B1 (en) 2017-04-19
CN101792525A (zh) 2010-08-04
KR20060054286A (ko) 2006-05-22
CN1822860A (zh) 2006-08-23
EP1648518A2 (en) 2006-04-26
DK2253330T3 (en) 2015-10-19
JP2012021003A (ja) 2012-02-02
ES2331004T3 (es) 2009-12-18
CN1822860B (zh) 2010-05-05
US9439974B2 (en) 2016-09-13
DK2133099T3 (en) 2017-07-31
JP5349552B2 (ja) 2013-11-20
WO2005007197A2 (en) 2005-01-27
US20060210526A1 (en) 2006-09-21
PL2253330T3 (pl) 2016-01-29
AU2010257308B2 (en) 2012-01-12
DE602004022824D1 (de) 2009-10-08
JP4958549B2 (ja) 2012-06-20
US20110182855A1 (en) 2011-07-28
CN101792525B (zh) 2012-06-06
AU2004257448B2 (en) 2010-09-23
JP2007527382A (ja) 2007-09-27
ATE440620T1 (de) 2009-09-15
EP2277550B1 (en) 2015-04-29
AU2010257308A1 (en) 2011-01-13
US20090298154A1 (en) 2009-12-03
WO2005007197A3 (en) 2005-03-31
DK2277550T3 (en) 2015-08-03
ES2549427T3 (es) 2015-10-28
US20140369960A1 (en) 2014-12-18
ES2542531T3 (es) 2015-08-06
EP2253330A2 (en) 2010-11-24
US8816051B2 (en) 2014-08-26
DK1648518T3 (da) 2009-11-09
EP2133099A3 (en) 2010-03-10

Similar Documents

Publication Publication Date Title
GB0316294D0 (en) Conjugated biological molecules and their preparation
CN101200504B (zh) 高分子巯基化改性衍生物及其交联材料
CA2191971A1 (en) Pegylation reagents and compounds formed therewith
WO2005065239A3 (en) Novel recombinant proteins with n-terminal free thiol
EA200000607A1 (ru) Конъюгаты эритропоэтина
AU5346896A (en) Heterotelechelic block copolymers and process for producing the same
DE60209560D1 (de) Thermoplastische zusammensetzung, welche einen hyperverzweigten polymer enthält, und daraus hergestellte gegenstände
AU5289096A (en) Polyethylene oxides having saccharide residue at one end and different functional group at another end, and process for producing the same
BR9915651A (pt) Processo para a preparação de ácidos alcanossulfÈnicos.
FI972326A0 (fi) Uusi amidinonaftyylijohdannainen tai sen suola
ES2195510T3 (es) Derivados de imidazopiridina y procedimiento para prepararlos.
DE69022176D1 (de) Zwischenverbindung für 2-alkynyladenosinherstellung, herstellung dieser zwischenverbindung, herstellung von 2-alkynyladenosin aus diesem zwischenprodukt sowie stabiles 2-alkynyladenosinderivat.
AU1313295A (en) Aryl acetic acid derivatives
ATE276358T1 (de) Polypeptid-polymer konjugat
ATE489356T1 (de) Asymmetrischer kupferkomplex und dessen verwendung in cyclopropanierungsreaktion
ATE553141T1 (de) Neues polymer und herstellungsverfahren dafür
EP0739905A4 (en) POLYMERIZATION CATALYST AND METHOD FOR PRODUCING POLYSTYRENE WITH THIS CATALYST
Chen et al. Synthesis and characterization of novel kinds of polyethylene oxide drugs containing 5-fluorouracil and nitrogen mustard at one end and 4-amino-N-(2-pyrimidinyl) benzene sulfonamide at the other end
DE69607890D1 (de) Aromatische Hydroxamsäure-Verbindungen, ihre Herstellung und Verwendung
Bauer Hydroxocobalamins as biologically compatible donors of nitric oxide implicated in the acceleration of wound healing
DE69900528D1 (de) Herstellung von Di-tert-peroxiden
ATE232240T1 (de) Verfahren zur herstellung von l-allysin acetal
ATE232222T1 (de) Verträglich machendes agens und methode zur herstellung desselben
WO2002092615A3 (en) Compositions and methods for array-based genomic nucleic acid analysis of biological molecules
ATE249434T1 (de) Ein verfahren zur herstellung von pyrrolidinon- derivaten

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)